Table 1.
Key clinical trials of immune checkpoint inhibitors in hepatocellular carcinoma.
| Check Point Inhibitor | Study | Significance/Outcome | Ongoing Clinical Trials | ||||
|---|---|---|---|---|---|---|---|
| Complete Response | Partial Response | Stable Disease | Overall Survival | PFS | |||
| Tremelimumab | Sangro et al., (n = 21) [56] | 0% | 17.6% | ~59% | 8.2 months | 6.4 months |
NCT02519348 NCT03298451 |
| Tremelimumab + ablation | Duffy et al., (n = 32) [57] | -- | 26.3% | -- | 12.3 months | 7.4 months |
NCT02821754 NCT03482102 |
| Nivolumab | El-Khoueiry et al., (n = 48) [58] | 4.2% | 8.3% | -- | 15 months | 3.4 months | NCT03383458 |
| El-Khoueiry et al., (n = 214) [58] | 1.4% | 18.2% * | 45% | 83% alive at 6 months | 4.1 months | ||
| Pembrolizumab | Zhu et al., (n = 104) [15] | 1% | 16% | 44% | 54% alive at 1 year | 5.1 months |
NCT03062358 NCT02702414 NCT03163992 NCT03419481 NCT02595866 |
| Durvalumab | Wainberg ZA, et al., (n = 40) [66] | 0% | 10.3% | 23% | 13.2 months | -- |
NCT02519348 NCT03298451 |
| Durvalumab + tremelimumab | Kelley RK, et al., (n = 40) [67] | 0% | 15% | 45% | -- | -- |
NCT02519348 NCT03298451 |